Tradestie Institutional Equity Comparison Engine

ATYR vs ARTV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATYR Overall Edge

ATYR Captures Institutional Edge (2โ€“0 Pillars ยท 2โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ATYR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ARTV at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro) against ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ATYR N/M vs ARTV N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner ATYR
1Y +558.7% vs +17.5% ยท 52W Pos 62% vs 7%
Options & Structure Winner ATYR
UNCLASSIFIED (36th %ile IV) vs BREAKDOWN (<1st %ile IV)
ATYR NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
1M Return +2788.76%
1Y Return +558.7%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
ARTV NASDAQ
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.82
-3.54% 1D
Market Cap $198.2M
1M Return -35.14%
1Y Return +17.54%
Forward P/E N/M
Unified AI Score
48.5 / 100 HOLD
Tech 50.0 Fund 60.0 Flow 64.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ATYR +558.7% ARTV +17.54% Spread: +541.16 pp (ATYR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ATYR Revenue ARTV Revenue ATYR Op. Margin ARTV Op. Margin Margin Edge
FY2019 $0M N/A -5445.0% N/A ATYR
FY2020 $10M N/A -152.2% N/A ATYR
FY2022 $10M N/A -446.8% N/A ATYR
FY2023 $0M $30M -15557.8% -93.2% ARTV
FY2024 $0M $0M -28899.6% -26805.6% ARTV
FY2025 $0M N/A -40856.3% N/A ATYR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ATYR (2) vs ARTV (4)
Institutional Metric ATYR ARTV Criterion Row Winner
Market Capitalization Scale $15.6M $198.2M Larger Scale ARTV
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth ATYR
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -93.7% -43.6% Higher ROE ARTV
52-Week Range Position Momentum 62% ($0โ€“$8) 7% ($3โ€“$15) Stronger Trend ATYR
Beta / 30D Volatility Risk Regime -9.67ฮฒ ยท 13806% Vol 1.73ฮฒ ยท 114% Vol Lower Realized Risk ARTV
Unified Institutional Score Composite Signal 34.3 / 100 (SELL) 48.5 / 100 (HOLD) Higher Composite ARTV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ATYR vs ARTV Buy Guide
ATYR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ATYR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARTV BREAKDOWN
147d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ARTV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ATYR nor ARTV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.